Skip to main content
Toggle navigation
Login
Search
Home
Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Browse by Speaker
Browse by Speaker
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Y
Yamamoto, Noboru
Department of Experimental Therapeutics, National Cancer Center Hospital
Paper 23 - A PHASE IA/IB, DOSE-ESCALATION/EXPANSION STUDY OF THE MDM2-P53 ANTAGONIST BRIGIMADLIN (BI 907828) IN PATIENTS WITH SOLID TUMORS: SAFETY AND EFFICACY IN PATIENTS WITH LIPOSARCOMA
Location: The Auditorium, Level 3
Noboru Yamamoto
Favorite
Yamashiro, Darrell
Columbia University Irving Medical Center
Paper 08 - NETWORK-BASED INFERENCE IDENTIFIES PROGNOSTIC SIGNATURES AND DRUGS TARGETING MASTER REGULATORS OF DISTINCT CELL STATES IN OSTEOSARCOMA
Location: The Auditorium, Level 3
Darrell Yamashiro
Favorite
Yanchenko, Natalia
Sylvester Comprehensive Cancer Center
Paper 03 - RACIAL AND ETHNIC DISPARITIES IN PRESENTATION AND OUTCOMES OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS (GIST) IN THE ERA OF TARGETED THERAPY
Location: The Auditorium, Level 3
Natalia Yanchenko
Favorite
yang, Kuangying
Washington University
Paper 75 - MTA-COOPERATIVE PRMT5 INHIBITORS ARE EFFICACIOUS IN MTAP-DELETED MALIGNANTPERIPHERAL NERVE SHEATH TUMOR MODELS
Location: The Auditorium, Level 3
Kuangying yang
Favorite
yang, Liuzhang
Washington University
Paper 75 - MTA-COOPERATIVE PRMT5 INHIBITORS ARE EFFICACIOUS IN MTAP-DELETED MALIGNANTPERIPHERAL NERVE SHEATH TUMOR MODELS
Location: The Auditorium, Level 3
Liuzhang yang
Favorite
Yang, Valerie
Division of Medical Oncology, National Cancer Centre Singapore
Session 4: Medical and Pediatric Oncology Trials
Location: The Auditorium, Level 3
Valerie Yang
Favorite
Yedigaryan, Laura
Translational Cardiomyology Laboratory, Stem Cell and Developmental Biology, Department of Development and Regeneration, KU Leuven
Paper 11 - MIR-449A/340 REWIRE METABOLIC COMMITMENT OF FUSION-NEGATIVE RHABDOMYOSARCOMA VIA MITOCHONDRIAL PYRUVATE CARRIER INHIBITION
Location: The Auditorium, Level 3
Laura Yedigaryan
Favorite
Yoder, Alison
MDACC
Session 15: Awards Session
Location: The Auditorium, Level 3
Alison Yoder
Favorite
Paper 16 - HOW SHOULD RADIATION THERAPY BE INCORPORATED INTO THE MULTIDISCIPLINARY MANAGEMENT OF SOFT TISSUE SARCOMAS FOLLOWING AN UNPLANNED EXCISION?
Location: The Auditorium, Level 3
Alison Yoder
Favorite
Paper 90 - THE IMPACT OF TUMOR LOCATION AND RADIATION DOSE TO BOWEL ON THE RISK OF DEVELOPING GASTROINTESTINAL TOXICITIES WHEN TREATING ABDOMINOPELVIC SOFT TISSUE SARCOMAS WITH PREOPERATIVE RADIATION
Location: The Auditorium, Level 3
Alison Yoder
Favorite
Yoon, Janet
City of Hope Comprehensive Cancer Center
Paper 22 - A PHASE II STUDY OF CABOZANTINIB AND TEMOZOLOMIDE IN PATIENTS WITH UNRESECTABLE OR METASTATIC LEIOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMAS
Location: The Auditorium, Level 3
Janet Yoon
Favorite
Yustein, Jason
Aflac Cancer and Blood Disorders Center, Emory University
Paper 11 - MIR-449A/340 REWIRE METABOLIC COMMITMENT OF FUSION-NEGATIVE RHABDOMYOSARCOMA VIA MITOCHONDRIAL PYRUVATE CARRIER INHIBITION
Location: The Auditorium, Level 3
Jason Yustein
Favorite
Yu, Wendong
The University of Texas MD Anderson Cancer Center
Paper 76 - EVALUATION OF THE MASSPEC PEN TECHNOLOGY FOR MOLECULAR IDENTIFICATION OF BONE AND SOFT TISSUE SARCOMAS AND SURGICAL MARGIN ASSESSMENT
Location: The Auditorium, Level 3
Wendong Yu
Favorite
